- Home
- EYE vs REPL Comparison
EYE vs REPL Comparison
Compare EYE & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYE
- REPL
- Stock Information
- Founded
- EYE 1990
- REPL 2015
- Country
- EYE United States
- REPL United States
- Employees
- EYE N/A
- REPL N/A
- Industry
- EYE Ophthalmic Goods
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- EYE Health Care
- REPL Health Care
- Exchange
- EYE Nasdaq
- REPL Nasdaq
- Market Cap
- EYE 870.5M
- REPL 816.4M
- IPO Year
- EYE 2017
- REPL 2018
- Fundamental
- Price
- EYE $11.03
- REPL $10.80
- Analyst Decision
- EYE Buy
- REPL Strong Buy
- Analyst Count
- EYE 3
- REPL 4
- Target Price
- EYE $14.00
- REPL $17.00
- AVG Volume (30 Days)
- EYE 1.5M
- REPL 432.6K
- Earning Date
- EYE 11-06-2024
- REPL 11-12-2024
- Dividend Yield
- EYE N/A
- REPL N/A
- EPS Growth
- EYE N/A
- REPL N/A
- EPS
- EYE N/A
- REPL N/A
- Revenue
- EYE $2,177,092,000.00
- REPL N/A
- Revenue This Year
- EYE N/A
- REPL N/A
- Revenue Next Year
- EYE $2.96
- REPL $469.74
- P/E Ratio
- EYE N/A
- REPL N/A
- Revenue Growth
- EYE 20.66
- REPL N/A
- 52 Week Low
- EYE $9.56
- REPL $4.92
- 52 Week High
- EYE $24.11
- REPL $12.97
- Technical
- Relative Strength Index (RSI)
- EYE 52.65
- REPL 38.50
- Support Level
- EYE $11.38
- REPL $11.45
- Resistance Level
- EYE $11.93
- REPL $12.73
- Average True Range (ATR)
- EYE 0.62
- REPL 0.69
- MACD
- EYE 0.00
- REPL -0.16
- Stochastic Oscillator
- EYE 39.25
- REPL 8.82
About EYE National Vision Holdings Inc.
National Vision Holdings Inc is an optical retailer in the U.S. Its product portfolio includes eyeglasses and sunglasses, contact lenses, accessories, and other products. The company has two operating segments; Owned and Host segment includes company-owned brands America's Best and Eyeglass World, In America's Best stores, vision care services are provided by optometrists or by independent professional corporations and Host operating consist of Military and Fred Meyer which provide eye exams by independent optometrists, and the Legacy segment manages the operations of, and supplies inventory and lab processing services to Legacy retail Vision Centers. It earns a majority of its revenue from the Owned and Host segment.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.